Archive: September 2022

How We Manage Idiopathic Multicentric Castleman Disease

Overview • We recommend first-line treatment with anti–interleukin 6 (anti–IL-6) for all patients with idiopathic multicentric Castleman disease.  • We recommend enrollment of all patients with […]

A Narrative Review of Anti–SARS-CoV-2 Vaccines and Immune Thrombocytopenia: Be Aware, But Reassured

Abstract: Background: The COVID-19 pandemic gave rise to rapid development of anti–SARS-CoV-2 vaccines using established and new technologies. Immune thrombocytopenia (ITP) is a bleeding disorder that […]

How We Manage Grief

Introduction Extensive literature exists on coping with the death of a patient with cancer, with much of the focus on what to say to the patient’s […]

“Degriefing”

In this issue you will find a thoughtful and sobering essay by Drs Anthony Galanos and Matthew Labriola, my colleagues at Duke, called “How We Manage […]

Maintenance Therapy With PARP Inhibition in Ovarian Cancer

H&O  Which poly(ADP-ribose) polymerase (PARP) inhibitors are approved for use as maintenance therapy in ovarian cancer?  TH  Two PARP inhibitors are approved for use as frontline […]

Hyper-CVAD–Based Regimens in Adult Patients With Acute Lymphoblastic Leukemia

H&O  How was the hyper-CVAD regimen originally used? EJ  The hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen was developed by Kantarjian and colleagues at MD […]

The Effectiveness of Immune Checkpoint Inhibitors in the Neoadjuvant and Post-Neoadjuvant Breast Cancer Settings

H&O  Could you describe the design of the KEYNOTE-522 study?  LP  KEYNOTE-522 was a large, randomized, placebo-controlled phase 3 trial that tested pembrolizumab (Keytruda, Merck) as […]

Variability in Global Drug Prices

H&O  Why are drug prices in the United States so high?  ASK  Brand-name drug prices are on average approximately 2 to 4 times higher in the […]

Back to Archive